From Research findings to Therapeutic opportunity:
The study presented here suggests that Calycosin, by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation in cancer cells; (iii) augment and restore chemosensitivity in drug-resistant Human cancers; (iv) promote anti-tumor effect; and (v) enhance the efficacy of anticancer drug treatment.
Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing “Calycosin or its analogue either alone or in combination with 5-FU, or any other anticancer drugs” may be used to inhibit cancer progression (Figs. 1-3).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed information: How Calycosin decreases the expression of Dihydropyrimidine dehydrogenase (DPYD)?
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Natural product-derived combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: Calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali, decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 11/January/2017, 8.48 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com